Waterloo Capital L.P. Has $2.33 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Waterloo Capital L.P. grew its stake in Johnson & Johnson (NYSE:JNJ) by 11.7% in the fourth quarter, HoldingsChannel reports. The fund owned 16,098 shares of the company’s stock after acquiring an additional 1,681 shares during the period. Waterloo Capital L.P.’s holdings in Johnson & Johnson were worth $2,328,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Oregon Pacific Wealth Management LLC bought a new position in Johnson & Johnson in the 4th quarter worth approximately $949,000. Horan Securities Inc. raised its position in shares of Johnson & Johnson by 1.3% during the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after acquiring an additional 90 shares during the last quarter. Strategic Financial Concepts LLC lifted its stake in shares of Johnson & Johnson by 57.9% during the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock valued at $501,000 after acquiring an additional 1,271 shares during the period. Lord Abbett & CO. LLC bought a new position in Johnson & Johnson in the third quarter valued at about $69,859,000. Finally, KPP Advisory Services LLC increased its position in Johnson & Johnson by 4.7% in the fourth quarter. KPP Advisory Services LLC now owns 11,492 shares of the company’s stock worth $1,662,000 after purchasing an additional 515 shares during the period. 69.55% of the stock is owned by institutional investors.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent research reports. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday. Raymond James cut their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Stifel Nicolaus decreased their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $171.33.

Johnson & Johnson Price Performance

NYSE JNJ opened at $153.03 on Friday. The firm’s 50 day moving average is $159.75 and its 200-day moving average is $155.84. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $368.77 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.29 EPS. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.